NEWS
2010-08-23 FDA grants Orphan Drug Status for to-BBB's lead product2010-06-14 to-BBB receives positive opinion for Orphan Drug Designation
2010-05-31 i-Optics 2nd place in Dutch Innovation top 100
2010-05-20 to-BBB announces pilot study with Janssen Pharmaceutica
2010-04-19 ActoGeniX appoints new Chief Executive Officer
2010-04-08 Biocartis raises EUR 30 million
2010-03-23 Aquapharm appoints new CEO and closes financing round
2010-03-15 Avantium wins Clean Technology Business Award
2010-03-03 to-BBB and GSK to collaborate on brain delivery
2010-02-26 Avantium appoints former Shell CTO to its Supervisory Board
2010-02-10 Biocartis acquires Philips-platform
2010-01-06 f-star raises EUR 8m in extended Series A Financing
2009-12-22 to-BBB and Lundbeck to join forces on brain delivery of antibodies for CNS diseases
2009-12-16 Avantium appoints Gunnar Staaf as CEO Pharma
2009-12-02 Rainer Christine joins Aescap Venture as Partner
2009-11-06 Avantium and AMS start collaboration on Crystal Structure Prediction
2009-11-03 to-BBB signs collaboration with Genzyme
2009-10-15 Aescap leads financing of Biocartis
2009-10-09 ActoGeniX completes Phase 2A clinical trial of AG011
2009-09-17 to-BBB technology will be used by MedImmune to evaluate brain drug delivery mechanism
2009-09-11 ProtAffin AG granted patent in USA for lead anti-inflammatory product PA401
2009-08-20 ActoGeniX starts clinical trial in oral mucositis
2009-07-30 Aescap Venture invests in EOS
2009-07-09 NatureWorks and Avantium to Collaborate on a New Generation of Biobased Polymers
2009-05-14 ActoGeniX obtains IND approval
2009-05-01 f-star hires Kevin FitzGerald as new CEO
2009-04-27 ProtAffin completes EUR 14 million Financing Round
2009-04-02 Affectis and Mitsubishi Tanabe Pharma enter drug discovery collaboration
2009-02-11 Actogenix completes equity financing round of 13.5 million euro
2009-02-03 Blood-brain barrier company to-BBB moves into commercialization mode with new CEO Willem van Weperen
2009-01-29 Actogenix, levende pil tegen darmziekte
2009-01-23 ProtAffin AG granted patent in EU for lead anti-inflammatory product PA401
2009-01-22 Avantium launches the Crystalline, a new parallel system for crystallization research.
2009-01-21 Cosun and Avantium announce collaboration
2008-11-08 Dutch biotech company to-BBB and Taiwanese ITRI sign exclusive license agreement
2008-10-29 Avantium completes EUR 18 million financing
2008-09-22 Vivendy Announces Management and Board Changes
2008-09-17 Vivendy’s Treatment for Morbus Morquio (MPS IVA) Granted Orphan Drug Designation by FDA
2008-09-11 Actogenix announces start of phase 2a clinical trial
2008-09-05 ProtAffin AG granted Orphan Drug Designation in the US for lead anti-inflammatory product
2008-08-04 Aquapharm signes license deal with Croda
2008-07-18 ProtAffin AG receives Orphan Medicinal Product Designation from EMEA for PA401
2008-07-09 Aquapharm and Dr. Reddy’s Sign Commercial License Agreements
2008-07-08 Aquapharm and Dr. Reddy\'s Sign License Agreement
2008-06-23 Aescap Venture invests in Vivendy Therapeutics Ltd.
2008-06-16 Aquapharm CEO wins Ernst & Young Scotland entrepreneur of the year award 2008
2008-05-28 to-BBB invited to pitch at BioEquity Europe
2008-05-14 Actogenix completes manufacturing of clinical product
2008-05-14 ActoGeniX completes manufacturing of its clinical product AG011 and prepares for phase 2 clinical trial
2008-04-02 ProtAffin AG announces R&D collaboration with Intercell AG
2008-03-28 F-Star Buys Back Royalty Obligations. TVM Capital Joins Investor Syndicate
2008-03-13 f-star opens research site in Cambridge, UK
2008-02-04 Anders Waas appointed as VP business development Actogenix
2008-01-28 Appointment Supervisory Board
2007-12-19 3 antibody pioneers join f-star scientific advisory board
2007-11-29 F-Star raises EUR 3.0 M in a Second Closing
2007-11-16 Aescap Venture takes 25% stake in i-Optics
2007-10-15 Affectis starts phase II clinical trial
2007-09-12 Aescap leads investment in f-Star
2007-07-31 Aescap invests in new antibiotics
2007-07-07 Vivendy Therapeutics Ltd. signs exclusive Patent Licensing Agreement for the development of an Enzyme Replacement Therapy for Morbus Morquio
2007-07-04 Aescap invests EUR 4 M in TO-BBB
2007-05-07 Aescap leads investment in ProtAffin AG
2007-01-31 Aescap invests in Actogenix NV
2007-01-08 Starters in biotech populair bij investeerders
2007-01-08 Aescap ventures exeeds 100M level
2006-10-24 Venture leads 12 million euro financing in Affectis Pharmaceuticals AG














